Document:

Exhibit 10.2

 

AMENDMENT No. 2

TO

CLINICAL SUPPLY AND COOPERATION AGREEMENT

 

This Amendment to
the Clinical Supply and Cooperation Agreement (this “Amendment”) dated as of July 22, 2015 is by and between
Ritter Pharmaceuticals, Inc., a Delaware corporation (“Ritter”) and Ricerche Sperimentali Montale SpA, an Italian
company (“Ricerche”) and Inalco SpA, a Italian company (“Inalco”, together with Ricerche,
“RSM”).

 

PRELIMINARY
STATEMENTS

 

WHEREAS, Ritter
and RSM are parties to that certain Clinical Supply and Cooperation Agreement dated December 16, 2009 and amended by Amendment
No. 1 dated September 25, 2010 (together, the “CSCA”) pursuant to which RSM agreed to manufacture and supply
to Ritter active pharmaceutical ingredient form of GOS of higher purity (95% purity or higher) for use in Ritter Product (the “CSCA”);
and

 

WHEREAS, the
Parties mutually desire to further amend the CSCA to revise certain terms and to add new terms.

 

NOW, THEREFORE,
in consideration of the Preliminary Statements and the mutual covenants contained in this Amendment, the parties agree to amend
the CSCA as follows:

 

		1.	Definitions. All capitalized terms used but not otherwise defined herein shall have the
meaning set forth in the CSCA.

 

		2.	Amendment to the CSCA.

 

		(a)	New Section 2.5(A) is added between Section 2.5 and Section 2.6 as follows:

 

“Within ten (10) days following
the approval by the FDA of the New Drug Application (commercial marketing authorization in the United States) for the first Ritter
Product, Ritter shall pay RSM the sum of Four Hundred Thousand US Dollars (US $400,000) (“Regulatory Approval Payment”).”

 

		(b)	New Sections 3.6 is added as follows:

 

“From and after the Effective
Date of this Amendment, and not withstanding anything in the CSCA to the contrary, the purchase price for clinical supply of Improved
GOS shall be Two Hundred Fifty US Dollars (US $250) per kilo. The Improved GOS shall be supplied to Ritter by RSM in accordance
with the terms of the CSCA. Ritter shall issue a purchase order on or before the Effective Date of this Amendment for the purchase
of Three Hundred Fifty (350) kilos of Improved GOS for an aggregate purchase price of Eighty Seven Thousand Five Hundred Dollars
(US$87,500).”

 

    	 	1	 

     

    

 

		(c)	Section 5.2(a) is deleted in its entirety and replaced with the following:

 

“RSM hereby grants to Ritter
an exclusive option in the Field and in the Territory to assignment of all Improved GOS IP (“Exclusive Option”).
Ritter may exercise the Exclusive Option by paying RSM the sum of Eight Hundred Thousand US Dollars (US $800,000), which payment
shall be paid within ten (10) days following the Effective Date of this Amendment (“First Payment Option”).”

 

		(d)	Section 5.2(b) is deleted in its entirety and replaced with the following:

 

“Immediately following
receipt of the First Payment Option, (i) RSM shall execute and deliver all instruments of assignment and other documentation necessary
or reasonably requested by Ritter for the purpose of (1) assigning to Ritter the Improved GOS IP and Technical Information and/or
(2) perfecting and/or maintaining such assignment to Ritter and Ritter’s ownership rights in the Improved GOS and Technical
Information and (ii) RSM will perform at the request of Ritter all lawful acts and execute, acknowledge and deliver all documents,
including assignments, deemed necessary, useful or appropriate by Ritter to vest in Ritter the entire right, title and interest
in and to such Improved GOS IP and obtain and record title thereto and to enable Ritter to prepare, file and prosecute applications
for and obtain and defend patents, copyrights and other forms of intellectual property protection thereon, so that Ritter shall
be the sole owner of such Improved GOS IP in any and all countries in which Ritter may desire such protection.”

 

		(e)	The following clarification statement is added to the end of Section 5.2(c) as follow:

 

“For purposes of clarity,
the Second Option Payment shall be made in addition to the Regulatory Approval Payment.”

 

		(f)	New Article 5A is added between Article 5 and Article 6 as follows:

 

“5A.STOCK
ISSUANCE

 

In consideration for entering
into the Amendment to the CSCA and without further cash consideration from RSM, Ritter shall issue to RSM in a private transaction
One Hundred Thousand (100,000) shares of the common stock of Ritter (the “Shares”) within ninety (90) days of
the Effective Date of this Amendment pursuant to the terms of a stock purchase agreement. Such stock purchase agreement will contain
(a) a “lock up” agreement whereby RSM will agree not to sell the Shares until the earlier of (i) the public release
by Ritter of the final results of Ritter’s Phase IIb/III clinical trial of RP-G28 and (ii) the filing of Ritter’s Form
10-Q with the Securities and Exchange Commission for the fiscal quarter in which Ritter receives the results of its Phase IIb/III
clinical trial of RP-G28 and (b) investment and other warranties, representations and covenants on behalf of RSM as are usual and
customary in connection with the sale of securities in a private transaction in the United States. For purposes of clarity, the
issuance of Shares may only be issued following full execution of the stock purchase agreement.”

 

    	 	2	 

     

    

 

 

		3.	Effective Date of Amendment. This Amendment shall take effect following receipt of the approval
from the Board of Directors of Ritter which is anticipated to be on or before August 1, 2015.

 

		4.	Effect of Amendment. Except as amended in this Amendment, in all other respects the
CSCA shall remain in full force and effect and be unaffected by this Amendment.

 

*      *        *

 

[Signature Page Follows]

 

    	 	3	 

     

    

 

 

IN WITNESS WHEREOF, each of the
Parties has caused this Amendment to be executed by its duly authorized representative on the date first above written.

 

	RITTER PHARMACEUTICALS, INC.	 
	 	 	 	 
	By:	/s/ANDREW J. RITTER	 
	 	Name:	Andrew J. Ritter	 
	 	Title:	President	 
	 	 	 	 
	RICERCHE SPERIMENTALI MONTALE SPA,	 
	 	 	 	 
	By:	/s/ GIOVANNI CIPOLLETTI	 
	 	Name:	Giovanni Cipolletti	 
	 	Title:	 	 
	 	 	 	 
	INALCO SPA,	 
	 	 	 	 
	By:	/s/ GIOVANNI CIPOLLETTI	 
	 	Name:	Giovanni Cipolletti	 
	 	Title:	 	 

   

    	 	4Exhibit 10.3

 

August 14, 2015

 

Ellen Mochizuki

[REDACTED]

 

Dear Ellen:

 

It is a pleasure to extend to you an offer
of employment to join Ritter Pharmaceuticals, Inc. (“Ritter”), as Vice President, Finance. Your hire date will
be September 21, 2015. This position reports to Ira E. Ritter, Chief Strategic Officer and Chairman.

 

The primary duties and areas of responsibility
with which you will become involved have been discussed during your interviews. Please keep in mind these duties and responsibilities
may change from time to time at Ritter’s sole discretion. Your compensation for this full-time, exempt position will be an
annual base salary of $170,000.00, payable in accordance with Ritter’s standard payroll practices. You will also be eligible
to earn a bonus based upon the achievement of agreed upon performance objectives for each year. Ritter will review your base salary
and bonus opportunities at least annually for adjustments.

 

You will be eligible for Ritter’s
comprehensive benefits package, as set forth in Ritter Employee Handbook. You will learn more about benefits and other information
at your new employee orientation, but if you have any particular questions about the benefits package before deciding whether to
accept this offer, please contact Andrew Ritter, our President.

 

Upon the commencement of your employment
with Ritter, you are required to complete Form I-9, Employment Eligibility Verification, and show proof of your employment eligibility
and identity.

 

Perhaps the most important consideration
in making your career decision is the opportunity for personal development in a challenging and growing business environment. Although
no company can guarantee what the future holds, we believe that the opportunities with Ritter are outstanding in terms of growth,
responsibility and compensation. Your success, of course, depends in large part on your own job performance and your contributions
to the success of Ritter. Based upon your past accomplishments, and the enthusiastic reactions of those who spoke with you, we
believe that you have the potential to make a substantial contribution to our group. We also believe that we can provide a rewarding
and challenging opportunity for you.

 

While we hope that our relationship will
be long and mutually beneficial, it should be recognized that neither you, nor we, have entered into any contract of employment,
expressed or implied, for any specific term. Our relationship is one of voluntary employment at-will. At-will means
that the employment is for no set period of time. You may resign at any time, and Ritter may terminate the employment relationship
at any time, with or without advance notice, and with or without cause or reason. Similarly, Ritter may change your position, job
duties, the compensation arrangement between you and Ritter, and other terms and conditions of

 

     

     

    

 

E. Mochizuki

August 14, 2015

Page 2

 

employment with or without cause, and with
or without advance notice, at any time in its sole discretion. Your employment at-will status cannot be modified by anyone in the
company, unless done so by the Chief Executive Officer and only if done in a writing that expressly alters the at-will nature of
the employment relationship and that is signed by the Chief Executive Officer. By accepting this offer, you are agreeing to the
at-will nature of your employment relationship with Ritter, and you are acknowledging that no one has made any promises or commitments
to you contrary to the foregoing.

 

Ellen, we would like to welcome you to
our team and hope that you will consider our offer favorable. To indicate your acceptance, please sign and return this letter to
me by the close of business on August 20, 2015. If you will be faxing your acceptance, please fax only this second page (signature
page) to fax number (310) 919-1600.

 

Sincerely,

 

	RITTER PHARMACEUTICALS, INC.	 
	 	 	 
	By:	/s/IRA E. RITTER	 
	 	Ira E. Ritter, Chief Strategic Officer and Chairman	 
	 	 	 
	ACCEPTANCE	 
	 	 	 
	By:	/s/ELLEN MOCHIZUKI	 
	 	Ellen Mochizuki	 
	 	 	 
	 	8/19/2015	 
	 	Signature Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}]]